Adrian Apostol, Lazar Chisavu, Nicolae Albulescu, Dana Stoian, Adalbert Schiller
RAS Inhibition in Haemodyalisis Patients. Impact on mortality
Abstract:
Patients with chronic kidney disease (CKD) represent a special category of risk. As part of the renal and cardiovascular continuum from risk factors to end stage diseases, they develop clinical syndromes with potentially severe prognosis. Patients on dialysis have severe cardiac risk, have a peculiar hyperlipemic profile with intense atherogenic effect, phosphocalcic metabolic alterations and thus a higher rate of development of atheroma and degenerative valve diseases. They have higher cardiovascular mortality and morbidity being potential candidates for aggressive reduction of risk factors. Dialysate patients are exposed to higher risk of ischemic and arrhythmic events. Echocardiographic assessment of these patients is extremely important in risk stratification and treatment strategy in order to improve prognosis. Drugs proved to improve cardiac remodeling, reduce hypertrophy and LV mass and enhance ejection fraction, improved prognosis.
Cite this article as: APOSTOL, A., CHISAVU, L., ALBULESCU, N., STOIAN, D., SCHILLER, A., RAS Inhibition in Haemodyalisis Patients. Impact on mortality, Rev. Chim., 70(2), 2019, 442-444.
Vancouver Apostol A, Chisavu L, Albulescu N, Stoian D, Schiller A. RAS Inhibition in Haemodyalisis Patients. Impact on mortality. Rev. Chim.[internet]. 2019 Feb;70(2):442-444. Available from: https://doi.org/10.37358/RC.19.2.6931
APA 6th edition Apostol, A., Chisavu, L., Albulescu, N., Stoian, D. & Schiller, A. (2019). RAS Inhibition in Haemodyalisis Patients. Impact on mortality. Revista de Chimie, 70(2), 442-444. https://doi.org/10.37358/RC.19.2.6931
Harvard Apostol, A., Chisavu, L., Albulescu, N., Stoian, D., Schiller, A. (2019). 'RAS Inhibition in Haemodyalisis Patients. Impact on mortality', Revista de Chimie, 70(2), pp. 442-444. https://doi.org/10.37358/RC.19.2.6931
IEEE A. Apostol, L. Chisavu, N. Albulescu, D. Stoian, A. Schiller, "RAS Inhibition in Haemodyalisis Patients. Impact on mortality". Revista de Chimie, vol. 70, no. 2, pp. 442-444, 2019. [online]. https://doi.org/10.37358/RC.19.2.6931
Text Adrian Apostol, Lazar Chisavu, Nicolae Albulescu, Dana Stoian, Adalbert Schiller, RAS Inhibition in Haemodyalisis Patients. Impact on mortality, Revista de Chimie, Volume 70, Issue 2, 2019, Pages 442-444, ISSN 2668-8212, https://doi.org/10.37358/RC.19.2.6931. (https://revistadechimie.ro/Articles.asp?ID=6931) Keywords: chronic kidney disease; hemodialysis; cardiovascular risk
RIS TY - JOUR T1 - RAS Inhibition in Haemodyalisis Patients. Impact on mortality A1 - Apostol, Adrian A2 - Chisavu, Lazar A3 - Albulescu, Nicolae A4 - Stoian, Dana A5 - Schiller, Adalbert JF - Revista de Chimie JO - Rev. Chim. PB - Revista de Chimie SRL SN - 2668-8212 Y1 - 2019 VL - 70 IS - 2 SP - 442 EP - 444 UR - https://doi.org/10.37358/RC.19.2.6931 KW - chronic kidney disease KW - hemodialysis KW - cardiovascular risk ER -
BibTex @article{RevCh2019P442, author = {Apostol Adrian and Chisavu Lazar and Albulescu Nicolae and Stoian Dana and Schiller Adalbert}, title = {RAS Inhibition in Haemodyalisis Patients. Impact on mortality}, journal = {Revista de Chimie}, volume = {70}, number = {2}, pages = {442-444}, year = {2019}, issn = {2668-8212}, doi = {https://doi.org/10.37358/RC.19.2.6931}, url = {https://revistadechimie.ro/Articles.asp?ID=6931} }
